4.4 Article

Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma

Journal

CANCER PREVENTION RESEARCH
Volume 14, Issue 3, Pages 313-324

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-20-0418

Keywords

-

Categories

Funding

  1. CCSG [P30 CA016672]
  2. Susan Gold Collins endowment
  3. Gil and Dody Weaver Foundation

Ask authors/readers for more resources

PD-1/PD-L1 pathway blockade and CD40 pathway activation were effective in preventing OPL progression into invasive OSCC in a murine model. Targeting of the CD40 and PD-1/PD-L1 pathways resulted in distinct patterns of immune modulation.
We have previously demonstrated that PD-1 blockade decreased the incidence of high-grade dysplasia in a carcinogen-induced murine model of oral squamous cell carcinoma (OSCC). It remains unknown, however, whether there are additional factors involved in escape from immune surveillance that could serve as additional targets for immunoprevention. We performed this study to further characterize the immune landscape of oral premalignant lesions (OPL) and determine the impact of targeting of the PD-1, CTLA-4, CD40, or OX40 pathways on the development of OPLs and oral carcinomas in the 4-nitroquinoline 1-oxide model. The immune pathways were targeted using mAbs or, in the case of the PD-1/PD-L1 pathway, using PD-L1-knockout (PD-L1(ko)) mice. After intervention, tongues and cervical lymph nodes were harvested and analyzed for malignant progression and modulation of the immune milieu, respectively. Targeting of CD40 with an agonist mAb was the most effective treatment to reduce transition of OPLs to OSCC; PD-1 alone or in combination with CTLA-4 inhibition, or PD-L1(ko), also reduced progression of OPLs to OSCC, albeit to a lesser extent. Distinct patterns of immune system modulation were observed for the CD40 agonists compared with blockade of the PD-1/PD-L1 axis with or without CTLA-4 blockade; CD40 agonist generated a lasting expansion of experienced/memory cytotoxic T lymphocytes and M1 macrophages, whereas PD-1/CTLA-4 blockade resulted in a pronounced depletion of regulatory T cells among other changes. These data suggest that distinct approaches may be used for targeting different steps in the development of OSCC, and that CD40 agonists merit investigation as potential immunoprevention agents in this setting. Prevention Relevance: PD-1/PD-L1 pathway blockade, as well as activation of the CD40 pathway, were able to prevent OPL progression into invasive OSCC in a murine model. A distinct pattern of immune modulation was observed when either the CD40 or the PD-1/PD-L1 pathways were targeted.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC

Jessica M. Konen, B. Leticia Rodriguez, Aparna Padhye, Joshua K. Ochieng, Laura Gibson, Lixia Diao, Natalie W. Fowlkes, Jared J. Fradette, David H. Peng, Robert J. Cardnell, Jeffrey J. Kovacs, Jing Wang, Lauren A. Byers, Don L. Gibbons

Summary: The study demonstrates that a novel combination of MEK and AXL inhibitors effectively bypasses EMT-mediated drug resistance in KRAS/p53-mutant non-small cell lung cancer by targeting EMT subpopulations, thereby preventing tumor cell survival.

CANCER RESEARCH (2021)

Article Multidisciplinary Sciences

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

David H. Peng, B. Leticia Rodriguez, Lixia Diao, Pierre-Olivier Gaudreau, Aparna Padhye, Jessica M. Konen, Joshua K. Ochieng, Caleb A. Class, Jared J. Fradette, Laura Gibson, Limo Chen, Jing Wang, Lauren A. Byers, Don L. Gibbons

Summary: Understanding the resistance mechanisms in mutant KRAS lung cancers to targeted therapies and immune checkpoint blockade is crucial for developing novel combination therapies. MEK inhibition combined with anti-PD-L1 can synergistically reduce lung tumor growth, but resistance may develop eventually. Increased Th17 cell infiltration in resistant tumors promotes invasiveness and resistance to MEK inhibitors, and a triple therapy targeting MEK, PD-L1, and IL-17 may overcome this resistance for better in vivo responses.

NATURE COMMUNICATIONS (2021)

Article Oncology

A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes

Carla Calagua, Miriam Ficial, Caroline S. Jansen, Taghreed Hirz, Luke del Balzo, Scott Wilkinson, Ross Lake, Anson T. Ku, Olga Voznesensky, David B. Sykes, Philip J. Saylor, Huihui Ye, Sabina Signoretti, Haydn Kissick, Adam G. Sowalsky, Steven P. Balk, David J. Einstein

Summary: A subset of primary prostate cancer expresses PD-L1 and exhibits immunogenic characteristics. Immunogenic prostate cancer shows comparable CD8(+) T-cell content with renal cell carcinoma, potentially driven by genomic losses of RBI, BRCA2, and CHD1.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses

Siang-Boon Koh, Brian N. Dontchos, Veerle Bossuyt, Christine Edmonds, Simona Cristea, Nsan Melkonjan, Lindsey Mortensen, Annie Ma, Kassidy Beyerlin, Elyssa Denault, Elizabeth Niehoff, Taghreed Hirz, David B. Sykes, Franziska Michor, Michelle Specht, Constance Lehman, Leif W. Ellisen, Laura M. Spring

Summary: Systematic collection of fresh tissues for research during diagnostic breast biopsy is safe, feasible, and efficient, providing a high-yield mechanism for diverse interdisciplinary research. The study demonstrated high diagnostic concordance between research and clinical specimens, consistent cell recovery, and potential clinical relevance in analyzing HER2 levels and immune microenvironment diversity.

NPJ PRECISION ONCOLOGY (2021)

Article Oncology

Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment

Youmna Kfoury, Ninib Baryawno, Nicolas Severe, Shenglin Mei, Karin Gustafsson, Taghreed Hirz, Thomas Brouse, Elizabeth W. Scadden, Anna A. Igolkina, Konstantinos Kokkaliaris, Bryan D. Choi, Nikolas Barkas, Mark A. Randolph, John H. Shin, Philip J. Saylor, David T. Scadden, David B. Sykes, Peter Kharchenko

Summary: Bone metastases are devastating complications of cancer, particularly common in prostate cancer and refractory to immunotherapy. Analysis of single cells reveals multifaceted immune distortion in metastatic prostate cancer, with overexpression of CCL20 by myeloid cells and appearance of unique macrophages specific to PCa bone metastases. Disruption of the CCL20-CCR6 axis restores T cell reactivity and prolongs animal survival in mice with syngeneic PCa bone metastases, suggesting a targeted approach for relieving local immunosuppression.

CANCER CELL (2021)

Review Respiratory System

Update 2021: Management of Small Cell Lung Cancer

Sara Tariq, So Yeon Kim, Jose Monteiro de Oliveira Novaes, Haiying Cheng

Summary: SCLC accounts for 14% of lung cancer cases and is highly aggressive with limited treatment options. Recent advances have identified potential therapeutic targets and subtypes, but further research is needed to improve treatment outcomes.
Review Cell Biology

Dance of The Golgi: Understanding Golgi Dynamics in Cancer Metastasis

Rakhee Bajaj, Amanda N. Warner, Jared F. Fradette, Don L. Gibbons

Summary: The Golgi apparatus plays a crucial role in protein processing and trafficking in normal cells. Aberrant Golgi dynamics in cancer alter the tumor microenvironment and the immune landscape, enhancing the invasive and metastatic potential of cancer cells.

CELLS (2022)

Article Multidisciplinary Sciences

A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma

Adele M. Alchahin, Shenglin Mei, Ioanna Tsea, Taghreed Hirz, Youmna Kfoury, Douglas Dahl, Chin-Lee Wu, Alexander O. Subtelny, Shulin Wu, David T. Scadden, John H. Shin, Philip J. Saylor, David B. Sykes, Peter V. Kharchenko, Ninib Baryawno

Summary: By analyzing ccRCC patient samples using single-cell transcriptomics, a distinct transcriptional signature predictive of metastatic potential and patient survival was identified. Potential therapeutic targets including the CXCL9/CXCL10-CXCR3 axis and the CD70-CD27 axis were highlighted.

NATURE COMMUNICATIONS (2022)

Article Oncology

Prevalence and Outcomes of COVID-19 among Hematology/Oncology Patients and Providers of a Community-Facing Health System during the B1.1.529 (Omicron) SARS-CoV-2 Variant Wave

Samuel A. Kareff, Aliya Khan, Priscila Barreto-Coelho, Sunil Girish Iyer, Brian Pico, Michele Stanchina, Giselle Dutcher, Jose Monteiro de Oliveira Novaes, Aparna Nallagangula, Gilberto Lopes

Summary: This study retrospectively evaluated the impact of COVID-19 on cancer patients and providers in a community-facing cancer clinic. The results showed a significantly higher COVID-19 positivity rate among providers compared to patients, with almost two-thirds of patients experiencing treatment delays and 10% of cancer patients dying during the Omicron wave. The study highlights the continued threat of COVID-19 to cancer patients' treatment and livelihood, as well as the healthcare disparities faced by disadvantaged populations.

CANCERS (2022)

Article Oncology

Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer

Kiranj Chaudagar, Hanna M. Hieromnimon, Rimpi Khurana, Brian Labadie, Taghreed Hirz, Shenglin Mei, Raisa Hasan, Jordan Shafran, Anne Kelley, Eva Apostolov, Ghamdan Al-Eryani, Kate Harvey, Srikrishnan Rameshbabu, Mayme Loyd, Kaela Bynoe, Catherine Drovetsky, Ani Solanki, Erica Markiewicz, Marta Zamora, Xiaobin Fan, Stephan Schuer, Alex Swarbrick, David B. Sykes, Akash Patnaik

Summary: This study aimed to elucidate the resistance mechanism to androgen deprivation therapy (ADT) and PI3K/AKT axis blockade in PTEN/p53-deficient metastatic castrate-resistant prostate cancer (mCRPC), and to develop rational combination strategies. The results showed that the combination of ADT and PI3Ki significantly enhanced anticancer responses by stimulating immune cell activation and reducing immune suppression of tumor-associated macrophages.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis

Mabel Perez-Oquendo, Roxsan Manshouri, Yanhua Tian, Jared J. Fradette, B. Leticia Rodriguez, Samrat T. Kundu, Don L. Gibbons

Summary: Epithelial-to-mesenchymal transition enables epithelial cells to acquire invasive capacity. The transcription repressor ZEB1 suppresses the expression of epithelial genes by binding to the E-boxes in gene promoter regions. Mass spectrometry analysis identified K811 acetylation as a novel posttranslational modification in ZEB1. Acetylation of ZEB1 promotes protein stability, interaction with other protein complexes, and the invasion/metastasis of lung adenocarcinoma through epithelial-to-mesenchymal transition.

MOLECULAR CANCER RESEARCH (2023)

Article Multidisciplinary Sciences

Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses

Taghreed Hirz, Shenglin Mei, Hirak Sarkar, Youmna Kfoury, Shulin Wu, Bronte M. Verhoeven, Alexander O. Subtelny, Dimitar V. Zlatev, Matthew W. Wszolek, Keyan Salari, Evan Murray, Fei Chen, Evan Z. Macosko, Chin-Lee Wu, David T. Scadden, Douglas M. Dahl, Ninib Baryawno, Philip J. Saylor, Peter V. Kharchenko, David B. Sykes

Summary: The treatment of low-risk primary prostate cancer only requires active surveillance, while high-risk disease necessitates multimodal treatment including surgery, radiation therapy, and hormonal therapy. Recurrence and metastatic disease development remain clinical challenges due to immune escape and tumor progression mechanisms that are not well understood. Through single-cell RNA sequencing and spatial transcriptomic analyses, we comprehensively describe the tumor microenvironment in localized prostate cancer and its differences compared to adjacent normal samples and healthy controls. Our study reveals an immune suppressive tumor microenvironment characterized by suppressive myeloid populations, exhausted T-cells, and high stromal angiogenic activity. We also infer cell-to-cell relationships within undissociated tissue sections using ligand-receptor interaction measurements. Overall, our work provides a highly detailed and comprehensive resource on the prostate tumor microenvironment and tumor-stromal cell interactions.

NATURE COMMUNICATIONS (2023)

No Data Available